These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 15151910)

  • 1. Cognitive decline with chronic meningitis secondary to a COX-2 inhibitor.
    Ashton D; Kim P; Griffiths N; Beran R
    Age Ageing; 2004 Jul; 33(4):408-9. PubMed ID: 15151910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.
    Wolfe F; Zhao S; Pettitt D
    J Rheumatol; 2004 Jun; 31(6):1143-51. PubMed ID: 15170928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central nervous system side effects of nonsteroidal anti-inflammatory drugs. Aseptic meningitis, psychosis, and cognitive dysfunction.
    Hoppmann RA; Peden JG; Ober SK
    Arch Intern Med; 1991 Jul; 151(7):1309-13. PubMed ID: 2064481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular thrombotic events and COX-2 inhibitors: results in patients with osteoarthritis receiving rofecoxib.
    Bannwarth B; Ravaud P; Dougados M
    J Rheumatol; 2003 Feb; 30(2):421-2. PubMed ID: 12583353
    [No Abstract]   [Full Text] [Related]  

  • 5. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.
    Florentinus SR; Heerdink ER; de Boer A; van Dijk L; Leufkens HG
    Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):437-41. PubMed ID: 15937867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter.
    Davies NM; Jamali F
    J Pharm Pharm Sci; 2004 Oct; 7(3):332-6. PubMed ID: 15576013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Is there a future for COX-2 inhibitors?].
    Yodfat Y
    Harefuah; 2004 Nov; 143(11):820-4, 837. PubMed ID: 15603272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study.
    Bogaty P; Brophy JM; Noel M; Boyer L; Simard S; Bertrand F; Dagenais GR
    Circulation; 2004 Aug; 110(8):934-9. PubMed ID: 15302800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aseptic meningitis associated with rofecoxib.
    Bonnel RA; Villalba ML; Karwoski CB; Beitz J
    Arch Intern Med; 2002 Mar; 162(6):713-5. PubMed ID: 11911727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lithium intoxication as a result of an interaction with rofecoxib.
    Rätz Bravo AE; Egger SS; Crespo S; Probst WL; Krähenbühl S
    Ann Pharmacother; 2004; 38(7-8):1189-93. PubMed ID: 15187206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells.
    Niederberger E; Manderscheid C; Grösch S; Schmidt H; Ehnert C; Geisslinger G
    Biochem Pharmacol; 2004 Jul; 68(2):341-50. PubMed ID: 15194006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analgesic effects of cyclooxygenase 2 inhibitors].
    Jayr C
    Bull Cancer; 2004 May; 91 Spec No():S125-31. PubMed ID: 15239341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer prevention: a new era beyond cyclooxygenase-2.
    Rigas B; Kashfi K
    J Pharmacol Exp Ther; 2005 Jul; 314(1):1-8. PubMed ID: 15805430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent ibuprofen-induced aseptic meningitis.
    Nguyen HT; Juurlink DN
    Ann Pharmacother; 2004 Mar; 38(3):408-10. PubMed ID: 14742833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse oral reactions associated with the COX-2 inhibitor rofecoxib.
    Bagán JV; Thongprasom K; Scully C
    Oral Dis; 2004 Nov; 10(6):401-3. PubMed ID: 15533219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib.
    Goldstein JL; Eisen GM; Agrawal N; Stenson WF; Kent JD; Verburg KM
    Aliment Pharmacol Ther; 2004 Sep; 20(5):527-38. PubMed ID: 15339324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
    Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent aseptic meningitis due to different non-steroidal anti-inflammatory drugs including rofecoxib.
    Ashwath ML; Katner HP
    Postgrad Med J; 2003 May; 79(931):295-6. PubMed ID: 12782779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of non-selective, non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors on the PFA-100 closure time.
    Blaicher AM; Landsteiner HT; Zwerina J; Leitgeb U; Volf I; Hoerauf K
    Anaesthesia; 2004 Nov; 59(11):1100-3. PubMed ID: 15479319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.